GoodRx Holdings, Inc. Q4 FY2025 earnings call

Management noted the fourth quarter marked a strong finish with disciplined execution across strategic priorities. Expanded direct-to-consumer affordability programs with pharma manufacturers, scaled differentiated subscription offerings, and deepened relationships with retail pharmacies. Highlighted the evolution of the business around pharma manufacturer solutions as a key growth driver, with PharmaDirect reflecting the shift in pharmaceutical commercialization. Also mentioned progress in Rx Marketplace, strength in subscriptions, and introduction of Employer Direct

Pharma manufacturer solutions full year revenue up more than 40% year over year. Rx Marketplace saw important progress in stabilizing and deepening partnerships with retail pharmacies in Q4. Subscription business focuses on condition-based strategy in high-intent areas like ED, hair loss, weight loss

2026 revenue expected to be in range of $750 - $780 million, adjusted EBITDA at least $230 million. Expect pressure on prescription transactions revenue in 2026 due to trade-offs in investing in pharma direct and subscriptions. Pharma direct revenue expected to grow at least 30% in 2026. Monthly active consumers expected to flatten sequentially from Q4 2025 through Q4 2026

Risks include factors from the risk factors section of the annual report on Form 10-K, such as known and unknown risks, uncertainties, and factors that could cause actual results to differ from forward-looking statements. Also includes potential impacts from changes in healthcare landscape, pharma budget spending environment, and competition in the market

Q: Dive in on revenue guidance, unit economics, recontracting efforts.

A: Chris explained factors driving PTR decline, stabilizing volume, and long-term durable approach.

Q: On pharma budget spending environment.

A: Laura and Chris discussed pharma budget pull forward, healthy budgets, and bookings growth in PharmaDirect.

Q: On business model change, legacy business.

A: Wendy and Laura talked about core being foundational, evolution towards pharma direct and employer direct, and importance of retail relationships.

Q: On PTR take rate, script degradation.

A: Chris explained stabilizing volume, renegotiating across supply chain, and holistic approach.

Q: On Lilly deal, pharma direct models.

A: Wendy and Laura discussed not commenting on specific deals, pharma manufacturers' direct-to-consumer efforts, and GoodRx's role in supporting them.

Q: On margin pressure, spending.

A: Chris and Wendy talked about cost of revenue mix, elective spending on new offerings, and optimizing marketing spend.

Q: On generic side, price stability.

A: Wendy discussed engaging consumers and bidirectional flow of dollars, and importance of pharma direct in price stability.

Q: On volume reduction in integrated savings programs.

A: Chris explained lapping impact, macroeconomic factors, and watching for positive trends.

Q: On web traffic, app usage, subscription composition.

A: Wendy and Laura discussed GLP-1 impact, brand price page views growth, and growth of subscription offerings.

Q: On PharmaDirect penetration, budget durability.

A: Laura talked about manufacturer partnerships, concentration of revenue, and typical distribution of spend.

Q: On subscription uptake, marketing spend.

A: Wendy and Chris discussed growth of subscription offerings, marketing spend on condition-specific subs, and influence of pharma price points